Skip to main content
SpringerLink
Log in

Anti-Parkinsonian Drugs Today

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

The drug treatment of Parkinson’s disease has progressed through 3 main stages: firstly, the use of anticholinergic drugs and amantadine; then the introduction of levodopa and its association with peripheral decarboxylase inhibitors; and finally the use of direct acting dopamine agonist drugs. Levodopa, however, remains the most effective single drug in Parkinson’s disease. Unfortunately, the side effects associated with long term levodopa treatment today constitute an important cause of functional disability. ‘Positive’ side effects such as involuntary movements and psychiatric disorder remain difficult to manage without causing an increase in Parkinsonian immobility; conversely, management of the ‘negative’ phenomenon of the ‘off’ period is limited by these same side effects. This has generated renewed interest in the highly complex pharmacokinetic and pharmacodynamic properties of levodopa, with the aim of reducing fluctuations in plasma levodopa (and hence brain dopamine) concentrations by sustained release oral or continuous parenteral administration of the drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Agid, Y.; Pollak, P.; Bonnet, A-M.; Signoret, J-L. and Lhermitte, F.: Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson’s disease. Lancet 1: 570–572 (1979).

    CAS  PubMed  Google Scholar 

  • Agid, Y.; Ruberg, M.; Dubois, D. and Javoy-Agid, F.: Biochemical substrates of mental disturbances in Parkinson’s disease. Advances in Neurology 40: 211–218 (1984).

    CAS  PubMed  Google Scholar 

  • Ballard, P.; Langston, J.W.; Tetrud, J. and Burns, R.S.: Chemically induced chronic parkinsonism in young adults: Clinical and neuropharmacological aspects. Neurology 33(Suppl. 2): 90 (1983).

    Google Scholar 

  • Barbeau, A.: L-Dopa therapy in Parkinson’s disease: A critical review of 9 years’ experience. Canadian Medical Association Journal 101: 59–68 (1969).

    CAS  PubMed  Google Scholar 

  • Barbeau, A.; Gillo-Joffroy, L. and Mars, H.: Treatment of Parkinson’s disease with levodopa and Ro 4-4602. Clinical Pharmacology and Therapeutics 12: 353–359 (1971).

    CAS  PubMed  Google Scholar 

  • Barbeau, A.; Sourkes, T.L. and Murphy, G.F.: Les catécholamines dans la maladie de Parkinson; in de Ajuriaguerra (Ed.) Mono-amines et Système Nerveux Central (Masson, Paris 1962).

    Google Scholar 

  • Bartholini, G.; Burkard, W.P.; Pletscher, A. and Bates, H.M.: Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature 215: 852–853 (1967).

    CAS  PubMed  Google Scholar 

  • Bedard, P.; Parkes, J.D. and Marsden, C.D.: Efffect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson’s disease and spontaneous dyskinesias. British Medical Journal 1: 954–956 (1978).

    CAS  PubMed  Google Scholar 

  • Berkowitz, D.M. and McCallum, R.W.: Interaction of levodopa and metoclopramide on gastric emptying. Clinical Pharmacology and Therapeutics 27: 414–420 (1980).

    CAS  PubMed  Google Scholar 

  • Besser, G.M. and Wass, J.A.H.: Pleuro-pulmonary shadows on bromocriptine. Lancet 1: 323 (1981).

    CAS  PubMed  Google Scholar 

  • Bevan, D.R.; Monks, P.S. and Calne, D.B.: Cardiovascular reactions to anaesthesia during treatment with levodopa. Anaesthesia 28: 29–31 (1973).

    CAS  PubMed  Google Scholar 

  • Birket-Smith, E.: Abnormal involuntary movements induced by anticholinergic therapy. Acta Neurologica Scandinavica 50: 801–811 (1974).

    CAS  PubMed  Google Scholar 

  • Birket-Smith, E.: Abnormal involuntary movements in relation to anti-chlinergics and levodopa therapy. Acta Neurologica Scandinavica 52: 158–160 (1975).

    CAS  PubMed  Google Scholar 

  • Birket-Smith, E. and Andersen, J.V.: Treatment of side-effects of levodopa. Lancet 1: 431 (1973).

    CAS  PubMed  Google Scholar 

  • Birkmayer, W.: Experimentelle ergebnesse uber die kombinationsbehandlung des Parkinson syndroms mit L-DOPA und einem Decarboxylasehemmer (Ro 4-4602). Wiener Klinische Wochenschrift 81: 677–679 (1969).

    CAS  PubMed  Google Scholar 

  • Birkmayer, W. and Hornykiewicz, O.: Der L-3,4-Dioxyphenylalanine (= DOPA) — Effekt bei der Parkinson-akinese. Wiener Klinische Wochenschrift 73: 787–788 (1961).

    CAS  PubMed  Google Scholar 

  • Birkmayer, W.; Riederer, P.; Youdim, M.B.H. and Linauer, W.: The potentiation of the anti-akinetic effect after levodopa treatment by an inhibitor of MAO-B, deprenyl. Journal of Neural Transmission 36: 303–326 (1975).

    CAS  PubMed  Google Scholar 

  • Bjorklund, A.; Stenevi, U.; Dunnett, S.B. and Gage, F.H.: Cross-species neural grafting in a rat model of Parkinson’s disease. Nature 298: 652–654 (1982).

    CAS  PubMed  Google Scholar 

  • Boller, F.; Mizutani, T.; Roessmann, U. and Gambbetti, P.: Parkinson’s disease, dementia and Alzheimer’s disease: Clinicopathological correlations. Annals of Neurology 7: 329–335 (1980).

    CAS  PubMed  Google Scholar 

  • Brogden, R.V.; Carmine, A.A.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Domperidone: A review of its pharmacological activity, phrmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 24: 360–400 (1982).

    CAS  PubMed  Google Scholar 

  • Callaghan, N.; Fitzpatrick, E. and O’Mahoney, J.B.: Piribedil (ET 495) in the treatment of Parkinson’s disease combined with amantadine or levodopa. Acta Neurologica Scandinavica 52: 179–186 (1975).

    CAS  PubMed  Google Scholar 

  • Calne, D.B.; Petrie, A.; Rao, S.; Reid, J.L. and Vakil, S.D.: Action of L-alphamethyldopa-hydrazine on the blood pressure of patients receiving levodopa. British Journal of Pharmacology 44: 162–164 (1972).

    CAS  PubMed  Google Scholar 

  • Calne, D.B.; Plotkin, C.; Williams, A.C.; Nutt, J.G.; Neophytides, A. and Teychenne, P.F.: Long-term treatment of parkinsonism with bromocriptine. Lancet 1: 735–738 (1978).

    CAS  PubMed  Google Scholar 

  • Calne, D.B.; Reid, J.L.; Vakil, S.D.; Rao, S.; Petrie, A.; Pallis, C.A.; Gawler, J.; Thomas, P.K. and Hilson, A.: Idiopathic parkinsonism treated with an extra-cerebral decarboxylase inhibitor in combination with levodopa. British Medical Journal 3: 729–732 (1971).

    CAS  PubMed  Google Scholar 

  • Calne, D.B.; Teychenne, P.F.; Claveria, L.E.; Eastman, R.; Greenacre, J.K. and Petrie, A.: Bromocriptine in parkinsonism. British Medical Journal 4: 442–444 (1974).

    CAS  PubMed  Google Scholar 

  • Caraceni, T.A.; Celano, J.; Parati, E. and Girotti, F.: Bromocriptine alone or associated with L-dopa and benserazide in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 40: 1142–1146 (1977).

    CAS  Google Scholar 

  • Celesia, G.G. and Wanamaker, W.M.: Psychiatric disturbances in Parkinson’s disease. Diseases of the Nervous System 33: 577–583 (1972).

    CAS  PubMed  Google Scholar 

  • Chase, T.N.: Fusaric acid in Parkinson’s disease. Neurology 24: 637–639 (1974).

    CAS  PubMed  Google Scholar 

  • Claveria, L.E.; Calne, D.B. and Allen, J.G.: “On-off” phenomena related to high plasma levodopa. British Medical Journal 1: 641–643 (1973).

    Google Scholar 

  • Clemens, J.A.; Shaar, C.J.; Smalstig, E.B.; Bach, N.J. and Kornfeld, E.C.: Inhibition of prolactin secretion by ergolines. Endocrinology 94: 1171–1176 (1974).

    CAS  PubMed  Google Scholar 

  • Coffey, C.E.; Ross, D.R.; Ferren, E.L.; Sullivan, J.L. and Olanow, C.W.: Treatment of the “on-off” phenomenon in Parkinsonism with lithium carbonate. Annals of Neurology 12: 375–379 (1982).

    CAS  PubMed  Google Scholar 

  • Cooper, D.R.; Marrel, C.; Testa, B.; Van de Waterbeemd, H.; Quinn, N.; Jenner, P. and Marsden, C.D.: L-Dopa methyl ester — a candidate for chronic systemic delivery of L-dopa in Parkinson’s disease. Clinical Neuropharmacology 7: 89–98 (1984).

    CAS  PubMed  Google Scholar 

  • Corrodi, H.; Fuxe, K; Hokfelt, T., Lidbrink, P. and Ungerstedt, U.: Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. Journal of Pharmacy and Pharmacology 25: 409–412 (1973).

    CAS  PubMed  Google Scholar 

  • Corrodi, H.; Fuxe, K. and Ungerstedt, U.: Evidence for a new type of dopamine receptor stimulating agent. Journal of Pharmacy and Pharmacology 23: 989–991 (1971).

    CAS  PubMed  Google Scholar 

  • Corsini, G.U.; Gessa, G.L.; del Zompo, M. and Mangoni, A.: Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. Lancet 1: 954–956 (1979).

    CAS  PubMed  Google Scholar 

  • Cotler, S.; Holazo, A.; Boxenbaum, H.G. and Kaplan, S.A.: Influence of route of administration and physiological availability of levodopa in dogs. Journal of Pharmaceutical Sciences 65: 822–827 (1976).

    CAS  PubMed  Google Scholar 

  • Cotzias, G.C.: Parkinsonism and DOPA. Journal of Chronic Diseases 22: 297–301 (1969).

    CAS  PubMed  Google Scholar 

  • Cotzias, G.C.; Papavasiliou, P.S.; Tolosa, E.S.; Mendez, J.S. and Belmidura, M.: Treatment of Parkinson’s disease with aporphines. Possible role of growth hormone. New England Journal of Medicine 294: 567–572 (1976).

    CAS  PubMed  Google Scholar 

  • Cotzias, G.C.; Van Woert, M.H. and Schiffer, L.M.: Aromatic amino acids and modification of Parkinsonism. New England Journal of Medicine 276: 374–379 (1967).

    CAS  PubMed  Google Scholar 

  • Crawley, J.C.W.; Smith, T.; Veall, N.; Zanelli, G.D.; Crow, T.J. and Owen, F.: Dopamine receptors displayed in living human brain with 77 Br-p-bromospiperone. Lancet 2: 975 (1983).

    CAS  PubMed  Google Scholar 

  • Critchley, E.: Levodopa and amantadine in the treatment of Parkinsonism. Practitioner 208: 499–504 (1972).

    CAS  PubMed  Google Scholar 

  • Csanda, E.; Antal, J.; Antony, M. and Csanaky, A.: Experiences with L-deprenyl in parkinsonism. Journal of Neural Transmission 43: 263–269 (1978).

    CAS  PubMed  Google Scholar 

  • Curzon, G.; Friedel, J.; Grier, L.; Marsden, C.D.; Parkes, J.D.; Shipley, M. and Zilkha, K.J.: Sustained-release levodopa in parkinsonism. Lancet 1: 781 (1973).

    CAS  PubMed  Google Scholar 

  • Dalen, P. and Steg, G.: Lithium and levodopa in parkinsonism. Lancet 1: 936–937 (1973).

    CAS  PubMed  Google Scholar 

  • Daniel, P.M.; Moorhouse, S.R. and Pratt, O.E.: Do changes in blood levels of other aromatic amino acids influence levodopa therapy? Lancet 1: 95 (1976).

    CAS  PubMed  Google Scholar 

  • Davis, G.C.; Williams, A.C.; Markey, S.P.; Ebert, M.H.; Caine, E.D.; Reichert, C.M. and Kopin, I.J., Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Research 1: 249–254 (1979).

    CAS  PubMed  Google Scholar 

  • De Cecco, L.; Foglia, G.; Ragni, N.; Rossato, P. and Venturini, P.L.: The effect of lisuride hydrogen maleate in the hyper-prolactinaemia-amenorrhoea syndrome: Clinical and hormonal responses. Clinical Endocrinology 9: 491–498 (1978).

    PubMed  Google Scholar 

  • Diamond, S.G.; Markham, C.H. and Techlokas, L.J.: A double-blind comparison of levodopa, Madopa and Sinemet in Parkinson disease. Annals of Neurology 3: 263–272 (1978).

    Google Scholar 

  • Direnfeld, L.K.; Feldman, R.G.; Alexander, M.P. and Kelly-Hayes, M.: Is L-dopa drug holiday useful? Neurology 30: 785–788 (1980).

    CAS  PubMed  Google Scholar 

  • Dorris, R.L. and Dill, R.E.: Inhibition of catechol-O-methyl transferase by N-butyl gallate. Neuropharmacology 16: 631–634 (1977).

    CAS  PubMed  Google Scholar 

  • Duby, S.E.; Cotzias, G.C.; Papavasiliou, P.S. and Lawrence, W.H.: Injected apomorphine and orally administered levodopa in parkinsonism. Archives of Neurology 27: 474–480 (1972).

    CAS  PubMed  Google Scholar 

  • Duvoisin, R.C.: Cholinergic-anticholinergic antagonism in parkinsonism. Archives of Neurology 17: 124–136 (1967).

    CAS  PubMed  Google Scholar 

  • Duvoisin, R.C.: Digital vasospasm with bromocriptine. Lancet 2: 204 (1976).

    CAS  PubMed  Google Scholar 

  • Duvoisin, R.C. and Heikkila, R.E.: Pergolide-induced circling in rats with 6-hydroxydopamine lesions of the nigro-striatal pathway. Neurology 31(Suppl. 2): 133 (1981).

    Google Scholar 

  • Duvoisin, R.C. and Katz, R.: Reversal of central anticholinergic syndrome in man by physostigmine. Journal of the American Medical Association 206: 1963–1965 (1968).

    CAS  PubMed  Google Scholar 

  • Duvoisin, R.C. and Mytilineou, C.: Where is L-dopa decarboxylated in the striatum after 6-hydroxydopamine nigrotomy? Brain Research 152: 369–373 (1978).

    CAS  PubMed  Google Scholar 

  • Duvoisin, R.C.; Yahr, M.D. and Cote, L.J.: Pyridoxine reversal of levodopa effects in parkinsonism. Transactions of the American Neurological Association 94: 81 (1969).

    CAS  PubMed  Google Scholar 

  • Eckstein, D.; Shaw, K. and Stern, G.: Sustained-release levodopa in parkinsonism. Lancet 1: 431–432 (1973).

    CAS  PubMed  Google Scholar 

  • Ehringer, H. and Hornykiewicz, O.: Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Wiener Klinische Wochenschrift 38: 1236 (1960).

    CAS  Google Scholar 

  • Eisler, T.; Eng, M.; Plotkin, C. and Calne, D.B.: Absorption of levodopa after rectal administration. Neurology 31: 215–217 (1981a).

    CAS  PubMed  Google Scholar 

  • Eisler, T.; Hall, R.P.; Kalavar, K.A.R. and Calne, D.B.: Erythromelalgia-like eruption in parkinsonian patients treated with bromocriptine. Neurology 31: 1368–1370 (1981b).

    CAS  PubMed  Google Scholar 

  • Ericsson, A.D.: Potentiation of the L-dopa effect in man by the use of catechol-O-methyl transferase inhibitors. Journal of Neurological Sciences 14: 193–197 (1971).

    CAS  Google Scholar 

  • Evans, M.A.; Triggs, E.J.; Broe, G.A. and Saines, N.: Systemic availability of orally administered L-dopa in the elderly parkinsonian patient. European Journal of Clinical Pharmacology 17: 215–221 (1980).

    CAS  PubMed  Google Scholar 

  • Fahn, S.: “On-of” phenomenon with levodopa therapy in parkinsonism. Neurology 24: 431–441 (1974).

    CAS  PubMed  Google Scholar 

  • Fahn, S.; Cote, L.J.; Snider, S.R.; Barrett, R.E. and Isgreen, W.P.: The role of bromocriptine in the treatment of parkinsonism. Neurology 29: 1077–1083 (1979).

    CAS  PubMed  Google Scholar 

  • Fahn, S.; Craddock, G. and Kumin, G.: Acute toxic psychosis from suicidal overdosage of amantadine. Archives of Neurology 25: 45–48 (1971).

    CAS  PubMed  Google Scholar 

  • Fahn, S. and David, E.: Oro-facio-lingual dyskinesia due to anticholinergic medication. Transactions of the American Neurological Association 97: 277–279 (1972).

    Google Scholar 

  • Fermaglich, J. and O’Doherty, D.S.: Effect of gastric motility on levodopa. Diseases of the Nervous System 33: 624–625 (1972).

    CAS  PubMed  Google Scholar 

  • Fleming, P.; Makar, H. and Hunter, K.R.: Levodopa in drug-induced extra-pyramidal disorders. Lancet 2: 1186 (1970).

    CAS  PubMed  Google Scholar 

  • Friedman, Z. and Neumann, E.: Benzhexol-induced blindness in Parkinson’s disease. British Medical Journal 1: 605 (1972).

    CAS  PubMed  Google Scholar 

  • Friis, M.L.; Gron, U.; Larsen, N.E.; Pakkenberg, H. and Hvidberg, E.F.: Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson’s disease. European Journal of Clinical Pharmacology 15: 275–280 (1979).

    CAS  PubMed  Google Scholar 

  • Fuller, R.W.; Clemens, J.A.; Kornfeld, E.C.; Snoddy, H.D.; Smalstig, E.B. and Bach, N.J.: Effects of (8β)-8-[(methylthio) methyl]-6-propylergoline on dopaminergic function and brain dopamine turnover in rats. Life Sciences 24: 375–382 (1979).

    CAS  PubMed  Google Scholar 

  • Galea-Debono, A.; Marsden, C.D.; Asselman, P. and Parkes, J.D.: Bromocriptine and dopamine receptor stimulation. British Journal of Clinical Pharmacology 3: 977–982 (1976).

    Google Scholar 

  • Garnett, E.S.; Firnau, G. and Nahmias, C.: Dopamine visualized in the basal ganglia of living man. Nature 305: 137–138 (1983).

    CAS  PubMed  Google Scholar 

  • Gillespie, N.G.; Mena, I.; Cotzias, G.C. and Bell, M.H.: Diets affecting treatment of parkinsonism with levodopa. Journal of the American Dietetic Association 62: 525–528 (1973).

    CAS  PubMed  Google Scholar 

  • Gilligan, B. and Hancock, R.: Enteric-coated L-dopa (pro-dopa). A new approach to L-dopa therapy in Parkinson’s disease. Medical Journal of Australia 2: 824–826 (1975).

    CAS  PubMed  Google Scholar 

  • Gilligan, B.; Wodack, J.; Stark, R. and O’Halloran, M.: Comparison of enteric-coated levodopa with levodopa-carbidopa combination. A double-blind crossover trial. Medical Journal of Australia 25: 205–207 (1979).

    Google Scholar 

  • Glover, V.; Sandler, M.; Owen, F. and Riley, G.J.: Dopamine is a monoamine oxidase B substrate in man. Nature 265: 80–81 (1977).

    CAS  PubMed  Google Scholar 

  • Goetz, C.G., Sinemet skin rash. Clinical Neuropharmacology 7: 107–108 (1984).

    CAS  PubMed  Google Scholar 

  • Goetz, C.G.; Tanner, C.M. and Nausieda, P.A.: Weekly drug holiday in Parkinson disease. Neurology 31: 1460–1462 (1981).

    CAS  PubMed  Google Scholar 

  • Gopinathan, G.; Teravainen, H.; Dambrosia, J.M.; Ward, C.D.; Sanes, J.N.; Stuart, W.K.; Evarts, E.V. and Calne, D.B.: Lisuride in parkinsonism. Neurology 31: 371–376 (1981).

    CAS  PubMed  Google Scholar 

  • Graham, D.G.; Tiffany, S.M.; Bell, W.R. and Gutknecht, W.F.: Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C 1300 neuroblastoma cells in vitro. Molecular Pharmacology 14: 644–653 (1978).

    CAS  PubMed  Google Scholar 

  • Granerus, A.K.; Jagenburg, R.; Rodjer, S. and Svanborg, A.: Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose. Acta Medica Scandinavica 196: 459–463 (1974).

    CAS  PubMed  Google Scholar 

  • Grimes, J.D.; Delgado, M.R. and Gray, P.: Low-dose bromocriptine therapy in “de novo” Parkinson’s disease: Indications, dosage, initial response rate, and adverse effects. Neurology 33(Suppl. 2): 112 (1983).

    Google Scholar 

  • Hardie, R.J.; Lees, A.J. and Stern, G.M.: On/off fluctuations in Parkinson’s disease: A clinical and neuropharmacological study. Brain (In press, 1984).

    Google Scholar 

  • Hinterberger, H. and Andrews, C.J.: Catecholamine metabolism during oral administration of levodopa. Effects of the medication in Parkinson’s disease. Archives of Neurology 26: 245–252 (1972).

    CAS  PubMed  Google Scholar 

  • Hoehn, M.M. and Elton, R.L.: Is low-dosage bromocriptine effective in parkinsonism? Neurology 33(Suppl. 2): 112 (1983).

    Google Scholar 

  • Hoehn, M.M. and Rutledge, C.O.: Acute overdose with levodopa — clinical and biochemical consequences. Neurology 25: 792–794 (1975).

    CAS  PubMed  Google Scholar 

  • Hornykiewicz, O.: Brain transmitter changes in Parkinson’s disease; in Marsden and Fahn (Eds) Neurology II, Movement Disorders, pp. 41–58 (Butterworths, London 1982).

    Google Scholar 

  • Horowski, R. and Wachtel, H.: Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice. European Journal of Pharmacology 36: 373–383 (1976).

    CAS  PubMed  Google Scholar 

  • Horrocks, P.M.; Vicary, D.J.; Rees, J.E.; Parkes, J.D. and Marsden, C.D.: Anticholinergic withdrawal and benzhexol treatment in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 36: 936–941 (1973).

    CAS  Google Scholar 

  • Hughes, R.C.; Polgar, J.G.; Weightman, D. and Walton, J.N.: Levodopa in parkinsonism: The effects of withdrawal of anticholinergic drugs. British Medical Journal 2: 487–491 (1971).

    CAS  PubMed  Google Scholar 

  • Ilson, J.; Fahn, S. and Cote, L.J.: Painful dystonic spasms in Parkinson’s disease. Advances in Neurology 40: 395–398 (1984).

    CAS  PubMed  Google Scholar 

  • Indo, T. and Ando, K.: Metoclopramide-induced parkinsonism. Clinical characteristics of 10 cases. Archives of Neurology 39: 494–496 (1982).

    CAS  PubMed  Google Scholar 

  • Javoy-Agid, F.; Ruberg, M.; Taquet, H.; Bokobza, E.; Agid, Y.; Gaspar, P.; Berger, B.; N’Guyen-Legros, J.; Alvarez, C.; Gray, F.; Escourolle, R.; Scatton, B. and Rouquier, L.: Biochemical neuropathology of Parkinson’s disease. Advances in Neurology 40: 189–198 (1984).

    CAS  PubMed  Google Scholar 

  • Klawans, H.L.; Goetz, C. and Bergen, D.: Levodopa-induced myoclonus. Archives of Neurology 32: 331–334 (1975a).

    Google Scholar 

  • Klawans, H.L.; Goetz, G.C.; Volkman, P.; Nausieda, P.A. and Weiner, W.J.: Lergotrile in the treatment of parkinsonism. Neurology 28: 669–702 (1978).

    Google Scholar 

  • Klawans, H.L.; Ringel, S.P. and Shenker, D.: Failure of vitamin B6 to reduce the L-dopa effect in patients on a dopa-decarboxylase inhibitor. Journal of Neurology, Neurosurgery and Psychiatry 34: 682–686 (1971).

    CAS  Google Scholar 

  • Klawans, H.L.; Topel, J.L. and Bergen, D.: Deanol in the treatment of levodopa-induced dyskinesias. Neurology 25: 290–293 (1975b).

    CAS  PubMed  Google Scholar 

  • Klawans, H.L. and Weiner, W.J.: Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias. Journal of Neurology, Neurosurgery and Psychiatry 37: 427–430 (1974).

    Google Scholar 

  • Knoll, J.: The possible mechanisms of action of (−)deprenyl in Parkinson’s disease. Journal of Neural Transmission 43: 177–198 (1978).

    CAS  PubMed  Google Scholar 

  • Koller, W.C.: Alternate-day levodopa therapy in Parkinsonism. Neurology 32: 324–326 (1982).

    CAS  PubMed  Google Scholar 

  • Koller, W.C.; Weiner, W.J.; Nausieda, P.A. and Klawans, H.L.: Bromocriptine: Decreased clinical effects at higher dosages. Neurology 29: 1439–1440 (1979).

    CAS  PubMed  Google Scholar 

  • Koller, W.C.; Weiner, W.J.; Perlik, S.; Nausieda, P.A.; Goetz, C.G. and Klawans, H.L.: Complications of chronic levodopa therapy; long-term efficacy of drug holiday. Neurology 31: 473–476 (1981).

    CAS  PubMed  Google Scholar 

  • Laitinen, L.V.: Slowly absorbed L-dopa preparation in the treatment of parkinsonism. Acta Neurologica Scandinavica 49: 331–338 (1973).

    CAS  PubMed  Google Scholar 

  • Lang, A.E.; Quinn, N.; Brincat, S.; Marsden, C.D. and Parkes, J.D.: Pergolide in late-stage Parkinson disease. Annals of Neurology 12: 243–247 (1982).

    CAS  PubMed  Google Scholar 

  • Langston, J.W.; Ballard, P.; Tetrud, J.W. and Irwin, I.: Chronic parkinsonism in humans due to a product of meperidineanalog synthesis. Science 219: 979–980 (1983).

    CAS  PubMed  Google Scholar 

  • Lee, T.; Seeman, P.; Rajput, A.; Farley, I.J. and Hornykiewicz, O.: Receptor basis for dopaminergic supersensitivity in Parkinson’s disease. Nature 273: 59–61 (1978).

    CAS  PubMed  Google Scholar 

  • Lees, A.J.; Kohout, L.J.; Shaw, K.M.; Stern, G.M.; Elsworth, J.D. and Sandler, M.: Deprenyl in Parkinson’s disease. Lancet 2: 791–795 (1977).

    CAS  PubMed  Google Scholar 

  • Lees, A.J.; Lander, C.M. and Stern, G.M.: Tiapride and sulpiride in Parkinson’s disease. Lancet 2: 1205 (1978a).

    CAS  PubMed  Google Scholar 

  • Lees, A.J.; Shaw, K.M. and Stern, G.M.: Baclofen in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 41: 707–708 (1978b).

    CAS  Google Scholar 

  • Lees, A.J. and Stern, G.M.: Bromocriptine in treatment of levodopa-induced end-of-dose dystonia. Lancet 2: 215–216 (1980).

    CAS  PubMed  Google Scholar 

  • Lees, A.J. and Stern, G.M.: Sustained bromocriptine therapy in previously untreated patients with Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 44: 1020–1023 (1981).

    CAS  Google Scholar 

  • Leibowitz, M. and Lieberman, A.: Comparison of dopa decarboxylase inhibitor (carbidopa) combined with L-dopa and L-dopa alone on the cardiovascular system of patients with Parkinson’s disease. Neurology 25: 917–921 (1975).

    CAS  PubMed  Google Scholar 

  • Leibowitz, M.; Lieberman, A.; Goldstein, M.; Neophytides, A.; Kupersmith, M.; Gopinathian, G. and Mehl, S.: Cardiac effects of pergolide. Clinical Pharmacology and Therapeutics 30: 718–723 (1981).

    CAS  PubMed  Google Scholar 

  • Lemberger, L. and Crabtree, R.E.: Pharmacologic effects in man of a potent, long-acting dopamine receptor agonist. Science 205: 1151–1153 (1979).

    CAS  PubMed  Google Scholar 

  • Leon, A.D. and Spiegel, H.E.: The effect of antacid administration on the absorption and metabolism of levodopa. Journal of Clinical Pharmacology 12: 263–267 (1972).

    CAS  Google Scholar 

  • Lesser, R.P.; Fahn, S.; Snider, S.R.; Cote, L.J.; Isgreen, W.P. and Barrett, R.E.: Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29: 1253–1260 (1979).

    CAS  PubMed  Google Scholar 

  • Le Witt, P.A. and Calne, D.B. Pleuro-pulmonary changes during long-term bromocriptine treatment for Parkinson’s disease. Lancet 1: 44–45 (1981).

    Google Scholar 

  • Le Witt, P.A.; Ward, C.D.; Ursen, T.A.; Raphaelson, M.I.; Newman, R.P.; Foster, N.; Dambrosia, J. and Calne, D.B.: Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 32(Suppl. 2): 181 (1982).

    Google Scholar 

  • Lhermitte, F.; Agid, Y.; Signoret, J.L. and Studier, J.M.: Les dyskinesies de “debut et fin de dose” provoquées par la L-dopa. Revue Neurologique 133: 297–308 (1977).

    CAS  PubMed  Google Scholar 

  • Lhermitte, F.; Agid, Y. and Signoret, J-L.: Onset and end-of-dose levodopa induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Archives of Neurology 35: 261–263 (1978).

    CAS  PubMed  Google Scholar 

  • Lieberman, A.N.; Goldstein, M.; Gopinathan, G.; Leibowitz, M.; Neophytides, A.; Walker, R.; Hiesiger, E. and Nelson, J.: Further studies with pergolide in Parkinson disease. Neurology 32: 1181–1184 (1982).

    CAS  PubMed  Google Scholar 

  • Lieberman, A.N.; Goldstein, M.; Leibowitz, M.; Neophytides, A.; Gopinathan, G.; Walker, R. and Pact, V: Lisuride combined with levodopa in advanced Parkinson disease. Neurology 31: 1466–1469 (1981a).

    CAS  PubMed  Google Scholar 

  • Lieberman, A.; Goldstein, M.; Neophytides, A.; Kupersmith, M.; Leibowitz, M.; Zasorin, N.; Walker, R. and Kleinberg, D.: Lisuride in Parkinson disease: Efficacy of lisuride compared to levodopa. Neurology 31: 961–965 (1981b).

    CAS  PubMed  Google Scholar 

  • Lieberman, A.N.; Kupersmith, M.D.; Gopinathan, G.; Estey, E.; Goodgold, A. and Goldstein, M.: Bromocriptine in Parkinson disease: Further studies. Neurology 29: 363–369 (1979).

    CAS  PubMed  Google Scholar 

  • Lieberman, A.; Miyamoto, T.; Battista, A.F. and Goldstein, M.: Studies on the antiparkinsonian efficacy of lergotrile. Neurology 25: 459–462 (1975).

    CAS  PubMed  Google Scholar 

  • Markham, C.H. and Diamond, S.G.: Evidence to support early levodopa therapy in Parkinson disease. Neurology 31: 125–131 (1981).

    CAS  PubMed  Google Scholar 

  • Marks, J.: The Treatment of Parkinsonism with L-Dopa (Medical and Technical Publishing Co., Lancaster 1974).

    Google Scholar 

  • Marsden, C.D. and Parkes, J.D.: “On-off” effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1: 292–296 (1976).

    CAS  PubMed  Google Scholar 

  • Marsden, C.D.; Parkes, J.D. and Rees, J.E.: Long-term treatment of Parkinson’s disease with an extracerebral dopa decarboxylase inhibitor (L-alpha-methylhydrazine, MK 486) and levodopa. Advances in Neurology 3: 79–93 (1973).

    Google Scholar 

  • Marsh, G.G. and Markham, C.H.: Does levodopa alter depression and psychopathology in Parkinsonism patients? Journal of Neurology, Neurosurgery and Psychiatry 36: 925–935 (1973).

    CAS  Google Scholar 

  • Matta, R.J. and Wooten, G.F.: Pharmacology of fusaric acid in man. Clinical Pharmacology and Therapeutics 14: 541–546 (1973).

    CAS  PubMed  Google Scholar 

  • McLellan, D.L.; Chalmers, R.J. and Johnson, R.H: Clinical and pharmacological evaluation of the effect of piribedil in patients with parkinsonism. Acta Neurologica Scandinavica 51: 74–82 (1975).

    CAS  PubMed  Google Scholar 

  • Melamed, E.: Early morning dystonia — late side-effect of long-term L-dopa therapy in Parkinson’s disease. Archives of Neurology 36: 308–310 (1979).

    CAS  PubMed  Google Scholar 

  • Mena, I. and Cotzias, G.C.: Protein intake and treatment of Parkinson’s disease with levodopa. New England Journal of Medicine 292: 181–184 (1975).

    CAS  PubMed  Google Scholar 

  • Mena, I.; Court, J. and Cotzias, G.C.: Levodopa, involuntary movements and fusaric acid. Journal of the American Medical Association 218: 1829–1830 (1971).

    CAS  PubMed  Google Scholar 

  • Metzel, E. and Weitbrecht, W.D.: Die dopa-resorption in der therapie der Parkinsonschen erkrankung. Archiv für Psychiatrie und Nervenkrankheiten 219: 231–237 (1974).

    CAS  PubMed  Google Scholar 

  • Miller, E.: Deanol in the treatment of levodopa-induced dyskinesias. Neurology 24: 116–119. (1974).

    CAS  PubMed  Google Scholar 

  • Miller, E.M. and Nieburg, H.A.: L-tryptophan in the treatment of levodopa-induced psychiatric disorders. Diseases of the Nervous System 35: 20–23 (1974).

    CAS  PubMed  Google Scholar 

  • Mones, R.J.: An analysis of 6 patients with Parkinson’s disease who have been unresponsive to L-dopa therapy. Journal of Neurology, Neurosurgery and Psychiatry 36: 362–367 (1973).

    CAS  Google Scholar 

  • Morgan, J.P.; Bianchine, J.R.; Spiegel, H.E.; Rivera-Calimlim, L. and Hersey, R.M.: Metabolism of levodopa in patients with Parkinson’s disease. Archives of Neurology 25: 39–43 (1971).

    CAS  PubMed  Google Scholar 

  • Morgan, J.P.; Rivera-Calimlim, L.; Messiha, F.; Sundaresan, P.R. and Trabert, N.: Imipramine-mediated interference with levodopa absorption from the gastro-intestinal tract in man. Neurology 25: 1029–1034 (1975).

    CAS  PubMed  Google Scholar 

  • Morris, J.G.L; Parsons, R.L., Trounce, J.R. and Groves, M.J.: Plasma dopa concentrations after different preparations of levodopa in normal subjects. Bristish Journal Of Clinical Pharmacology 3: 983–990 (1976).

    CAS  Google Scholar 

  • Muenter, M.D.; Sharpless, N.S.; Tyce, S.M. and Darley, F.L.: Patterns of dystonia (“I-D-I” and “D-I-D”) in response to L-dopa therapy for Parkinson’s disease. Mayo Clinic Proceedings 52: 163–174 (1977).

    CAS  PubMed  Google Scholar 

  • Muenter, M.D. and Tyce, G.M.: L-dopa therapy for Parkinson’s disease: Plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clinic Proceedings 46: 231–239 (1971).

    CAS  PubMed  Google Scholar 

  • Narabyashi, H.; Kondo, T.; Hayashi, A.; Suzuki, T. and Nagatsu, T.: L-threo-3,4-dihydroxyphenylserine treatment for akinesia and freezing of parkinsonism. Proceedings of the Japanese Academy 57B: 351–354 (1981).

    Google Scholar 

  • Narabyashi, H.; Kondo, T. and Nagatsu, T.: L-threo-3,4-dihydroxyphenyl-serine treatment for akinesia and freezing of parkinsonism. Neurology 32(Suppl. 2): 180 (1982).

    Google Scholar 

  • Nastuk, W.L.; Su, P.C. and Doubilet, P.: Anticholinergic and membrane activities of amantadine in neuromuscular transmission. Nature 264: 76–79 (1976).

    CAS  PubMed  Google Scholar 

  • Nausieda, P.A.; Weiner, W.J. and Klawans, H.L.: Dystonic foot response of parkinsonism. Archives of Neurology 37: 132–136 (1980).

    CAS  PubMed  Google Scholar 

  • Nora, J.J.; Nora, A.H. and Way, G.L.: Cardiovascular maldevelopment associated with maternal exposure to amantadine. Lancet 2: 607 (1975).

    CAS  PubMed  Google Scholar 

  • Nutt, J.G. and Fellman, J.H.: Pharmacokinetics of levodopa. Clinical Neuropharmacology 7: 35–49 (1984).

    CAS  PubMed  Google Scholar 

  • Nutt, J.; Williams, A.; Plotkin, C.; Eng, N.; Ziegler, M and Calne, D.B.: Treatment of Parkinson’s disease with sodium valproate: Clinical, pharmacological and biochemical observations. Canadian Journal of Neurological Sciences 6: 337–343 (1979).

    CAS  PubMed  Google Scholar 

  • Nutt, J.G.; Woodward, W.R.; Hammerstad, J.P.; Carter, J.H. and Anderson, J.L.: The “on-off” phenomenon in Parkinson’s disease. Relation to levodopa absorption and transport. New England Journal of Medicine 310: 483–488 (1984).

    CAS  PubMed  Google Scholar 

  • Obeso, J.A.; Martinez-Lage, J.M.; Luquin, M.R. and Bolio, N.: Intravenous lisuride infusion for Parkinson’s disease. Annals of Neurology 14: 252 (1983).

    CAS  PubMed  Google Scholar 

  • Ordenstein, L.: Sur la paralysie agitante et la sclérose en plaques géneralisée. Doctoral Thesis, Martinet, Paris (1867).

    Google Scholar 

  • Pacifici, G.M.; Nardini, M.; Ferrari, P.; Latini, R.; Freschi, C. and Morselli, P.L.: Effect of amantadine on drug-induced parkinsonism: Relationship between plasma levels and effects. British Journal of Clinical Pharmacology 3: 883–889 (1976).

    CAS  PubMed  Google Scholar 

  • Parkes, J.D.; Curzon, G.; Knott, P.J.; Tatersall, R.; Baxter, R.C.H.; Knill-Jones, R.P.; Marsden, C.D. and Vollum D.: Treatment of Parkinson’s disease with amantadine and levodopa. A one year study. Lancet 1: 1083–1087 (1971).

    CAS  PubMed  Google Scholar 

  • Parkes, J.D.; Debono, A.G. and Marsden, C.D.: Bromocriptine in parkinsonism: Long-term treatment, dose response and comparison with levodopa. Journal of Neurology, Neurosurgery and Psychiatry 39: 1101–1108 (1976).

    CAS  Google Scholar 

  • Parkes, J.D.; Schachter, M.; Marsden, C.D.; Smith, B. and Wilson, A.: Lisuride in parkinsonism. Annals of Neurology 9: 48–52 (1981).

    CAS  PubMed  Google Scholar 

  • Parkes, J.D.; Tarsy, D.; Marsden, C.D.; Bovill, K.T.; Phipps, J.A.; Rose, P. and Asselman, P.: Amphetamines in the treatment of Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 38: 232–237 (1975).

    CAS  Google Scholar 

  • Parkes, J.D.; Zilkha, K.J.; Calver, D.M. and Knill-Jones, R.P.: Controlled trial of amantadine hydrochloride in Parkinson–s disease. Lancet 1: 259–262 (1970).

    CAS  PubMed  Google Scholar 

  • Pearce, J.: Mechanism of action of amantadine. British Medical Journal 3: 529 (1971).

    CAS  PubMed  Google Scholar 

  • Pentland, B. and Sawers, J.S.A.: Galactorrhoea after withdrawal of bromocriptine. British Medical Journal 2: 716 (1980).

    Google Scholar 

  • Perret, J.; Feuerstein, C.; Pellat, J.; Serre, F.; Gavend, M. and Tanche, M.: Résults des dosages de la méthoxydopa plasmatique chez les parkinsoniens avec ou sans dyskinésies induites par la L-dopa. Revue Neurologique 133: 627–636 (1977).

    CAS  PubMed  Google Scholar 

  • Perry, R.H.; Tomlinson, B.E.; Candy, J.M.; Blessed, G.; Foster, J.F.; Bloxham, C.A. and Perry, E.R.: Cortical cholinergic deficit in mentally impaired parkinsonian patients. Lancet 2: 789–790 (1983).

    CAS  PubMed  Google Scholar 

  • Pfeiffer, R.F.; Wilken, K.; Yates, C. and Lorenzo, A.S.: Low-dose bromocriptine in Parkinson’s disease. Neurology 33(Suppl. 2): 112 (1983).

    Google Scholar 

  • Pollak, T.; Gaio, J.M.; Hommel, M.; Pellat, J. and Chateau, R.: Etude aigue de l’association bromocriptine plus domperidone dans le syndrome parkinsonien. Thérapie 36: 671–676 (1981).

    CAS  PubMed  Google Scholar 

  • Porter, C.C.; Watson, L.S.; Titus, D.C.; Tolaro, J.A. and Byer, S.S.: Inhibition of dopa carboxylase by the hydrazine analog of methyl dopa. Biochem. Pharmacol. 11: 1067–1072 (1962).

    CAS  PubMed  Google Scholar 

  • Price, P.; Parkes, J.D. and Marsden, C.D.: Tiapride in Parkinson’s disease. Lancet 2: 1106 (1978a).

    CAS  PubMed  Google Scholar 

  • Price, P.; Parkes, J.D. and Marsden, C.D.: Sodium valproate in the treatment of levodopa-induced dyskinesia. Journal of Neurology, Neurosurgery and Psychiatry 41: 702–706 (1978b).

    CAS  Google Scholar 

  • Quinn, N.; Illas, A.; Lhermitte, F. and Agid, Y.: Bromocriptine and domperidone in the treatment of Parkinson disease. Neurology 31: 662–667 (1981a).

    CAS  PubMed  Google Scholar 

  • Quinn, N.; Illas, A.; Lhermitte, F. and Agid, Y.: Bromocriptine in Parkinson’s disease: A study of cardiovascular effects. Journal of Neurology, Neurosurgery and Psychiatry 44: 426–429 (1981b).

    CAS  Google Scholar 

  • Quinn, N.; Marsden, C.D. and Parkes, J.D.: Complicated response fluctuations in Parkinson’s disease: Response to continuous intravenous infusion of levodopa. Lancet 2: 412–415 (1982).

    CAS  PubMed  Google Scholar 

  • Quinn, N.; Parkes, J.D. and Marsden, C.D.: Control of the “on-off” phenomenon by continuous intravenous infusion of levodopa. Neurology (In press, 1984).

    Google Scholar 

  • Quinn, N.P.; Perlnutter, J.S. and Marsden, C.D.: Acute administration of DL Threo DOPS does not affect the freezing phenomenon in parkinsonian patients. Neurology 34(Suppl. 1): 149 (1984).

    Google Scholar 

  • Rabey, J.M.; Vardi, J.; Askenazi, J.J. and Streifler, M.: L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients. Gerontology 23: 438–444 (1977).

    CAS  PubMed  Google Scholar 

  • Rascol, A.; Montastruc, J.L.; Guiraud-Chaumeil, B. and Clanet, M.: La bromocriptine comme premier traitement de la maladie de Parkinson. Résultats à long terme. Revue Neurologique 138: 401–408 (1982).

    CAS  PubMed  Google Scholar 

  • Reavill, C.; Jenner, P. and Marsden, C.D.: Metabolite involvement in bromocriptine-induced circling behaviour in rodents. Journal of Pharmacy and Pharmacology 32: 278–284 (1980).

    CAS  PubMed  Google Scholar 

  • Reches, A. and Fahn, S.: Catechol-O-methyltransferase and Parkinson’s disease. Advances in Neurology 40: 171–179 (1984).

    CAS  PubMed  Google Scholar 

  • Reches, A.; Jackson, V. and Fahn, S.: DL-Threo-DOPS: Effective peripheral precursor of norepinephrine with no effect on brain levels of norepinephrine or dopamine. Neurology 34(Suppl. 1): 269 (1984).

    Google Scholar 

  • Richter, J.J. and Wainer, A.: Evidence for separate systems for the transport of neutral and basic amino acids across the blood-brain barrier. Journal of Neurochemistry 18: 613–620 (1971).

    CAS  PubMed  Google Scholar 

  • Rinne, U.K.: Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson’s disease. Lancet 1: 44 (1981).

    Google Scholar 

  • Rinne, U.K.; Koskinen, V. and Konnberg, P.: Neurotransmitter receptors in the parkinsonian brain; in Rinne et al. (Eds) Parkinson’s Disease — Current Progress, Problems and Management, pp.94–107 (Elsevier/North-Holland, Amsterdam 1980).

    Google Scholar 

  • Rinne, U.K.; Lonnberg, P. and Koskinen, V.: Dopamine receptors in the parkinsonian brain. Journal of Neural Transmission 51: 97–109 (1981).

    CAS  PubMed  Google Scholar 

  • Rinne, U.K. and Molsa, P.: Levodopa with benserazide or carbidopa in Parkinson disease. Neurology 29: 1584–1589 (1979).

    CAS  PubMed  Google Scholar 

  • Rinne, U.K.; Siirtola, T. and Sonninen, V. L-deprenyl treatment of on-off phenomena in Parkinson’s disease. Journal of Neural Transmission 43: 253–262 (1978).

    CAS  PubMed  Google Scholar 

  • Rinne, U.K. and Sonninen, V.: Brain catecholamines and their metabolites in parkinsonian patients. Archives of Neurology 28: 107–110 (1973).

    CAS  PubMed  Google Scholar 

  • Rinne, U.K.; Sonninen, V. and Siirtola, T.: Plasma concentration of levodopa in patients with Parkinson’s disease. European Neurology 10: 301–310 (1973).

    CAS  PubMed  Google Scholar 

  • Rivera-Calimlim, L.: L-dopa absorption and metabolism by the human stomach. Journal of Clinical Investigation 49: 799 (1970).

    Google Scholar 

  • Rivera-Calimlim, L.: Effect of chronic drug treatment on intestinal membrane transport of 14C-L-dopa. British Journal of Pharmacology 46: 708–713 (1972).

    CAS  PubMed  Google Scholar 

  • Rivera-Calimlim, L.; Dujovne, C.A.; Morgan, J.P.; Lasagna, L. and Bianchine, J.R.: L-dopa treatment failure: Explanation and correction. British Medical Journal 4: 93–94 (1970).

    CAS  PubMed  Google Scholar 

  • Rossor, M.N.; Watkins, J.; Brown, M.J.; Reid, J.L. and Dollery, C.T.: Plasma levodopa, dopamine and therapeutic response following levodopa therapy of parkinsonian patients. Journal of the Neurological Sciences 46: 385–392 (1980).

    CAS  PubMed  Google Scholar 

  • Ruberg, M.; Ploska, A.; Javoy-Agid, F. and Agid, Y.: Muscarinic binding and choline acetyl transferase activity in Parkinsonian subjects with reference to dementia. Brain Research 232: 129–139 (1982).

    CAS  PubMed  Google Scholar 

  • Saarinen, A.; Myllyla, V.V.; Tokola, O. and Hokkanen, E.: Effect of a slow release preparation of levodopa on Parkinson’s disease in combination with a peripheral decarboxylase inhibitor. Acta Neurologica Scandinavica 58: 340–349 (1978).

    CAS  PubMed  Google Scholar 

  • Sandier, M.: The dopa effect: Possible significance of transamination and tetrahydroisoquinoline formation. Advances in Neurology 2: 225–264 (1973).

    Google Scholar 

  • Schachter, M.; Bedard, P.; Debona, A.G.; Jenner, P.; Marsden, C.D.; Price, P.; Parkes, J.D.; Keenan, J.; Smith, B.; Rosenthaler, J.; Horowski, R. and Dorow, R.: The role of D-1 and D-2 receptors. Nature 286: 157–159 (1980a).

    CAS  PubMed  Google Scholar 

  • Schachter, M.; Marsden, C.D.; Parkes, J.D.; Jenner, P. and Testa, B.: Deprenyl in the management of response fluctuations in patients with Parkinson’s disease on levodopa. Journal of Neurology, Neurosurgery and Psychiatry 43: 1016–1021 (1980b).

    CAS  Google Scholar 

  • Schwab, R.S.; Amador, L.V. and Lettvin, J.Y.: Apomorphine in Parkinson’s disease. Transactions of the American Neurological Association 76: 251–253 (1951).

    Google Scholar 

  • Schwab, R.S.; England, A.C.; Poskanzer, D.C. and Young, R.R.: Amantadine in the treatment of Parkinson’s disease. Journal of the American Medical Association 208: 1168–1170 (1969).

    CAS  PubMed  Google Scholar 

  • Serby, M.; Angrist, D. and Lieberman, A.: Mental disturbances during bromocriptine and lergotrile treatment of Parkinson’s disease. American Journal of Psychiatry 135: 1227–1229 (1978).

    CAS  PubMed  Google Scholar 

  • Shealy, C.N.; Weeith, J.B. and Mercier, D.: Livedo reticularis in patients with parkinsonism receiving amantadine. Journal of the American Medical Association 212: 1522–1523 (1970).

    CAS  PubMed  Google Scholar 

  • Shindler, J.; Finnerty, G.; Jenner, P.; Lake-Bakaar, G. and Parkes, J.D.: Domperidone, metoclopramide and levodopa in Parkinson’s disease; in First Symposium of the European Neuroendocrine Association, Basel, March 4–7, p.42 (1984).

  • Shoulson, I.; Glaubiger, G.A. and Chase, T.N.: On-off response. Clinical and biochemical correlations during oral and intravenous levodopa adminisration in parkinsonian patients. Neurology 25: 1144–1148 (1975).

    CAS  PubMed  Google Scholar 

  • Sober, A.J. and Wick, M.M.: Levodopa therapy and malignant melanoma. Journal of the American Medical Association 240: 554–555 (1978).

    CAS  PubMed  Google Scholar 

  • Stromberg, U. and Svensson, T.H.: Further studies on the mode of action of amantadine. Acta Pharmacologica et Toxicologica 30: 161–171 (1971).

    CAS  PubMed  Google Scholar 

  • Sweet, R.D.; Lee, J.E.; Spiegel, H.E. and McDowell, F.: Enhanced response to low doses of levodopa after withdrawal from chronic treatment. Neurology 22: 520–525 (1972).

    CAS  PubMed  Google Scholar 

  • Sweet, R.D. and McDowell, F.H. Plasma dopa concentrations and the “on-off” effect after chronic treatment of Parkinson’s disease. Neurology 24: 953–956 (1974).

    CAS  PubMed  Google Scholar 

  • Tanner, C.M.; Chhablani, R.; Goetz, C.G. and Klawans, H.L.: Pergolide mesylate: Lack of cardiac toxicity in 6 patients with known cardiac disease. Neurology 32(Suppl. 2): 65 (1982a).

    Google Scholar 

  • Tanner, C.M.; Goetz, C.G.; Glantz, R.H.; Glatt, S.L. and Klawans, H.L.: Pergolide mesylate and idiopathic Parkinson disease. Neurology 32: 1175–1179 (1982b).

    CAS  PubMed  Google Scholar 

  • Tanner, C.M.; Goetz, C.G. and Klawans, H.L.: Paroxysmal drenching sweats in idiopathic Parkinsonism: Response to propranolol. Neurology 32(Suppl. 2): 162 (1982c).

    Google Scholar 

  • Teychenne, P.F.; Bergsrud, D.; Racy, A.; Elton, R.L. and Vern, B.: Bromocriptine: Low dose therapy in Parkinson disease. Neurology 32: 577–583 (1982).

    CAS  PubMed  Google Scholar 

  • Teychenna, P.F.; Calne, D.B.; Leigh, P.N.; Greenacre, J.K.; Reid, J.L.; Petrie, A. and Bamji, A.N.: Idiopathic parkinsonism treated with bromocriptine. Lancet 2: 473–476 (1975a).

    Google Scholar 

  • Teychenne, P.F.; Calne, D.B.; Lewis, P.J. and Findley, L.J.: Interactions of levodopa with inhibitors of monoamine oxidase and L-aromatic acid decarboxylase. Clinical Pharmacology and Therapeutics 18: 273–277 (1975b).

    CAS  PubMed  Google Scholar 

  • Teychenne, P.F.; Pfeiffer, R.F.; Bern, S.M.; McInturff, D. and Calne, D.B.: Comparison between lergotrile and bromocriptine in parkinsonism. Annals of Neurology 3: 319–324 (1978).

    CAS  PubMed  Google Scholar 

  • Timberlake, W.H. and Vance, M.A.: Four years treatment of patients with parkinsonism using amantadine alone or with levodopa. Annals of Neurology 3: 119–128 (1978).

    CAS  PubMed  Google Scholar 

  • Tolosa, E.; Martin, W.E.; Cohen, H.P. and Jacobson, R.L.: Patterns of clinical response and plasma dopa levels in Parkinson’s disease. Neurology 25: 177–183 (1975).

    CAS  PubMed  Google Scholar 

  • Tourtellotte, W.; Syndulko, K.; Potvin, A.R.; Hirsch, S.B. and Potvin, J.H.: Increased ratio of carbidopa to levodopa in treatment of Parkinson’s disease. Archives of Neurology 37: 723–726 (1980).

    CAS  PubMed  Google Scholar 

  • Trabucchi, M.; Bassi, S. and Frattola, L.: Effect of naloxone on the ‘on-off’ syndrome in patients receiving long-term levodopa therapy. Archives of Neurology 39: 120–121 (1982).

    CAS  PubMed  Google Scholar 

  • Ungerstedt, U.: Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiologica Scandinavica 82(Suppl. 367): 49–68 (1971).

    Google Scholar 

  • Vakil, S.D.; Calne, D.B.; Reid, J.L. and Seymour, C.A.: Pyrimidyl-piperonyl-piperazine (ET 495) in Parkinsonism. Advances in Neurology 3: 121–125 (1973).

    Google Scholar 

  • Vale, J.A. and Maclean, K.S.: Amantadine-induced heart failure. Lancet 1: 548 (1977).

    CAS  PubMed  Google Scholar 

  • Vollum, D.; Parkes, J.D. and Doyle, D.: Livedo reticularis during amantadine treatment. British Medical Journal 2: 627–628 (1971).

    CAS  PubMed  Google Scholar 

  • Von Voigtlander, P.F. and Moore, K.E.: Dopamine: Release from the brain in vivo by amantadine. Science 174: 408–410 (1971).

    Google Scholar 

  • Wade, D.N.; Mearrick, P.T.; Birkett, D.J. and Morris, J.: Variability of L-dopa absorption in man. Australian and New Zealand Journal of Medicine 4: 138–143 (1974).

    CAS  PubMed  Google Scholar 

  • Walker, J.E.; Potvin, A.; Tourtellotte, W.; Albers, J.; Repa, B.; Henderson, W. and Snyder, D.: Amantadine and levodopa in the treatment of Parkinson’s disease. Clinical Pharmacology and Therapeutics 13: 28–36 (1972).

    CAS  PubMed  Google Scholar 

  • Ward, C.D.; Trombley, I.K.; Calne, D.B. and Kopin, I.J.: L-dopa decarboxylation in chronically treated patients. Neurology 34: 198–201 (1984).

    CAS  PubMed  Google Scholar 

  • Wass, J.A.H.; Thorner, M.O. and Besser, G.M.: Digital vasospasm with bromocriptine. Lancet 1: 1135 (1976).

    CAS  PubMed  Google Scholar 

  • Weiner, W.J.; Koller, W.C.; Perlik, S.; Nausieda, P.A. and Klawans, H.L.: Drug holiday and management of Parkinson disease. Neurology 30: 1257–1261 (1980).

    CAS  PubMed  Google Scholar 

  • Weintraub, M.I.; Gaasterlan, D.D. and Van Woert, M.H.: Pupillary effects of levodopa therapy. Development of anisocoria in latent Horner’s syndrome. New England Journal of Medicine 283: 120–123 (1970).

    CAS  PubMed  Google Scholar 

  • Yahr, M.D.: Variations in the ‘on-off’ effect. Advances in Neurology 5: 397–399 (1974).

    CAS  PubMed  Google Scholar 

  • Yokochi, M.: Juvenile Parkinson’s disease. Part II. Pharmacokinetic study. Shinkei Shinpo 23: 1060–1073 (1979).

    Google Scholar 

  • Yoshida, H.; Kaniike, K. and Namba, J.: Properties of a carrier system to transport L-dopa into brain slices. Nature 198: 191–192 (1963).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Psychiatry and King’s College Hospital Medical School, University Department of Neurology, Denmark Hill, London, SE5 9RS, England

    Niall P. Quinn

Authors
  1. Niall P. Quinn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Quinn, N.P. Anti-Parkinsonian Drugs Today. Drugs 28, 236–262 (1984). https://doi.org/10.2165/00003495-198428030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198428030-00002

Keywords

Search

Navigation